Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G9MY
|
|||
| Drug Name |
CD33-specific gene-engineered T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1] | |
| Company |
Shenzhen Geno-Immune Medical Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.